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Targeting Tumor Stroma: Exploiting Apoptotic Priming 
Joachim C. Mertens and Gregory J. Gores
Difficulties in directly targeting tumor cells. 
Specific therapeutic targeting of cancer cells has been the 
holy grail of oncological research for decades. However, 
effective cancer cell directed therapy has proven difficult 
to achieve mainly due to the enormous multitude of 
genetic aberrations in many types of cancer. Given the 
vast number of inter-individual genetic variations and 
biologic behaviours of malignant cells, each tumor patient 
can be considered to have his own private and individual 
tumor. Genetic diversity has even been described between 
cancer cells within a single tumor nodule [1]. This has led 
to an ever increasing diversification and complexity of 
cancer therapy under the grand theme of ‘individualized 
medicine’. Individualized medicine has resulted in modest 
oncologic success such as EGFR and ALK targeted 
therapy in non-small cell lung cancer [2]. However, 
therapeutic progress has been slow despite considerable 
progress in DNA sequencing of cancers.
Tumor stroma as important factor in tumor 
biology – the tumor ‘ecosystem’. Malignant cells exist 
within a complex ‘ecosystem’ [3] consisting of a variety 
of cell types. Stromal cells of the tumor microenvironment 
have been shown to play a crucial role in tumor 
development, growth and metastasis . An important cell 
population aside from the malignant cells themselves are 
activated, α-smooth muscle actin positive fibroblasts of the 
tumor microenvironment. These cells, also called cancer 
associated fibroblasts or CAF provide growth factors, 
modify and secrete extracellular matrix and facilitate 
cancer cell survival and metastatic mobility [4]. Of the 
multitude of interactions between tumor and stromal 
cells, the secretion of PDGF and the extracellular matrix 
components tenascin C and periostin by CAF have been 
demonstrated to promote tumor growth and metastasis [5]. 
Also the number of CAF in the tumor microenvironment 
of cancer patients is inversely correlated with patient 
survival . Thus CAF are a potential therapeutic target in 
human cancers.
Concept of apoptotic priming. Activated cell states 
have been described to result in an increased cellular 
sensitivity towards apoptotic stimuli. This is known for 
T-cells, which become susceptible to apoptotic cell death 
upon activation [6] as well as activated hepatic stellate 
cells in acute liver injury. The phenomenon of increased 
apoptotic sensitivity has been termed ‘mitochondrial 
priming’, as apoptosis in these cells occurs though the 
mitochondrial pathway. Mitochondrial priming can be 
determined by assessing the mitochondrial release of 
apoptotgenic factors upon incubation with different pro-
apoptotic BH-3 peptides [8]. These peptides mimic the 
binding activities of BH3-only proteins, pro-apoptotic 
members of the Bcl-2 family of proteins, which trigger 
the mitochondrial apoptotic pathway. Still the underlying 
mechanisms of ‘mitochondrial priming’ are not well 
understood. Moreover tumor stroma cells have not been 
previously examined with respect to their potential 
mitochondrial priming during the process of their cellular 
activation.
Activated CAF display apoptotic priming. Given 
the above information, we sought to determine if CAF 
can be selectively targeted by pro-apoptotic therapy. 
We observed, that the paradigm of activation induced 
mitochondrial priming is also true for the activated CAF 
in the tumor microenvironment [7].  We profiled Bcl-2 
proteins in CAF and quiescent stromal cells and observed 
an increased expression of Bax, a potent multidomain pro-
apoptotic protein of the Bcl-2 family. We next employed 
the pro-apoptotic BH-3 mimetic navitoclax (ABT-263) 
and observed a strong induction of apoptosis in the CAF 
in vitro, while quiescent fibroblasts were completely 
unresponsive and malignant cell lines showed minimal 
sensitivity. Malignant cholangiocarcinoma cells are 
likely resistant to navitoclax as they overexpress Mcl-1, 
a potent anti-apoptotic Bcl-2 protein which does not bind 
navitoclax. The upregulation of Bax helps to prime the 
mitochondria, sensitizing CAF to navitoclax cytotoxicity. 
Interestingly we were able to generate a similar phenotype 
in previously quiescent fibroblasts by pretreating these 
cells with TGF-β, as TGF-β effectively activates and 
sensitizes them to navitoclax-induced apoptosis. Taken 
together, these observations suggest targeting tumor 
stroma cells with pro-apoptotic compounds represents a 
novel therapeutic approach in cancer.
Targeting tumor stroma with BH3 mimetics. 
To test the hypothesis of mitochondrial priming and 
sensitivity to pro-apoptotic therapeutics in vivo we 
employed a highly aggressive orthotopic, syngeneic 
animal model of cholangiocarcinoma. Indeed navitoclax 
did induce Bax activation, release of pro-apoptotic factors 
and apoptotic cell death primarily in activated CAF. 
Targeted deletion of CAF results in a secondary reduction 
of tumor size, metastasis and an improved animal survival 
(Fig. 1).
Perspectives of combined therapeutic 
approaches.  As effective and specific therapies targeting 
only the malignant cells are still a distant prospect in 
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many cancers, combination cancer therapies, targeting 
CAF and the cancer cells may be the more promising 
and realistic therapeutic objective. In this multimodal 
approach, the tumor stroma offers a more uniform, less 
genetically heterogeneous target that should be a focus of 
future therapeutic developments. Exploiting the apoptotic 
priming of tumor stromal cells combined with other tumor 
cell targeted therapies could be an elegant approach for the 
treatment of desmoplastic cancers. 
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Figure 1: Therapeutic deletion of CAF for the treatment 
of highly desmoplastic human cancers. Activated cancer 
associated fibroblasts, CAF, (spiculated orange cells)  display 
mitochondrial priming for apoptotic cell death – presumably due 
to upregulation of the pro-apoptotic Bcl-2 protein Bax. As such 
these cells can be targeted with a BH3 mimetic, inducing CAF 
apoptosis and subsequently depleting the cancer cells (green 
cells) of important stroma-derived survival signals.  The cancer 
cells then undergo secondary apoptosis. 
